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The blending together of synthetic chemistry with natural product biosynthesis represents a potentially
powerful approach to synthesis; to enable this, further synthetic tools and methodologies are needed.
To this end, we have explored the ﬁrst Sonogashira cross-coupling to halotryptophans in water. Broad
reaction scope is demonstrated and we have explored the limits of the scope of the reaction. We have
demonstrated this methodology to work excellently in the modiﬁcation of model tripeptides.
Furthermore, through precursor directed biosynthesis, we have generated for the ﬁrst time a new to
nature brominated natural product bromo-cystargamide, and demonstrated the applicability of our
reaction conditions to modify this novel metabolite.Introduction
Natural products represent a valuable resource for medicinally
relevant compounds, with many antimicrobial and antitumour
agents entering clinical trials being based on natural products.1
New approaches to modify natural products and generate
analogues are important, enabling, for example, structure
activity relationships to be probed, and the natural product's
bioactivity and bioavailability to be modulated, or enabling
natural product tagging for uorescence detection or immobi-
lisation.2a–d Palladium cross-coupling reactions are a powerful
tool in synthesis and potentially for late-stage analogue gener-
ation of natural products.3 We previously reported the rst
utilisation of Suzuki–Miyaura cross-coupling for the diversi-
cation of free, unprotected halotryptophans.2e Developing a new
GenoChemetic approach to natural product analogue genera-
tion, we showed how, through biosynthetic pathway manipu-
lation, a new to nature chlorinated antibiotic could be accessed
and reported on the utility of palladium cross-coupling reac-
tions for synthetic diversication of this chloro-uridyl peptide
antibiotic.2f In order to expand this GenoChemetic approachity of St Andrews, St Andrews, KY16 9ST,
ille, France
arch Saarland (HIPS), Microbial Natural
66123 Saarbru¨cken, Germany
SI) available: Experimental procedures;
ation. See DOI: 10.1039/c6sc04423a
hemistry 2017and our toolkit of compatible reactions, we set out to explore the
potential applicability of the Sonogashira cross-coupling reac-
tion.4 In this work, we wanted to examine, for the rst time,
whether the Sonogashira cross-coupling could be utilised to
selectively diversify unprotected halotryptophans. Through
biosynthetic pathway manipulation, we generated a new-to-
nature bromo-cystargamide, and set out to explore whether the
Sonogashira methodology that we had developed could be uti-
lised in selectively modifying bromo-tryptophan residues as
a component of a tripeptide or within our novel bromo natural
product (Scheme 1).
The Sonogashira cross-coupling reaction of aryl amino acid
derivatives has been shown to be important, enabling the
modication of proteins and peptides through an alkynyl
linker.5d,5f,5g,5i,5l,8,9 The reaction has also shown applicability in
tagging the proteins with uorescence labels (Scheme 1A),5a in
tagging for Fluorescence Resonance Energy Transfer (FRET)5c,10
and Positron Emission Tomography (PET) studies.5k Such
cross-coupling investigations within peptides, however, almost
exclusively focused on either the diversication of highly reac-
tive alkynyl derivatives embedded within peptides or iodo-
phenyl derivatives such as iodophenylalanine5 and iodo-tyrosi-
ne.5a,6 Strategies to exploit the Sonogashira reaction to modify
iodinated or alkynylated nucleic acids have also been success-
fully employed (Scheme 1B).5a,7 The reaction frequently
requires the use of protected substrates, however, Sonogashira
cross-coupling of unprotected amino acids, including iodo and
bromo phenylalanine and tyrosine were also reported.5l,6eChem. Sci., 2017, 8, 2039–2046 | 2039
Scheme 1 Sonogashira cross-coupling modiﬁcation of natural
product analogues. (A) Labelling of iodophenyl derivatives with ﬂuo-
rescent tags.9 (B) Cross-coupling of iodinated pyrimidine nucleoside.7a
(C) Sonogashira cross-coupling of unprotected bromotryptophans.
(D) Sonogashira cross-coupling of 7-bromotryptophan in a tripeptide
system. (E) New to nature bromo-cystargamide.
Fig. 1 Water soluble ligands for Pd mediated cross-coupling. sSPhos
11, sXPhos 12, TPPTS 13 and TXPTS 14.
Scheme 2 Sonogashira cross-coupling reaction of 5-bromoindole 15
with phenylacetylene 16. (a) Reagents and conditions are described in
Table 1.
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View Article OnlineThe intrinsic uorescence of tryptophan oen determines,
or modulates, the spectrophotometric properties of a given
peptide or protein; and is a crucial residue for stabilising
secondary and tertiary structure through intra and intermolec-
ular interactions.11 It is also an important residue in many
natural products. It is found in its halogenated form in a wide
variety of metabolites including anticancer agents Rebeccamy-
cin12 and diazonamide A.13 The possibility of selective chemical
modication of such residues within natural products and
peptides is attractive.14 However, though much research has
been carried out on the Sonogashira modication of hal-
ophenylalanines and halotyrosines, to the best of our knowl-
edge, there are no prior reports of the utilisation of this strategy
for the Sonogashira diversication of more challenging halo-
tryptophans, either as a discrete amino acid or as a component
of a peptide or natural product.
Halotryptophans may be readily accessed through a simple
one-step biotransformation using tryptophan synthase,15,16 or
through a 4–5 step chemical synthesis.17 Challenges that need
to be addressed to render Sonogashira cross-coupling of free
halotryptophans useful are their poor solubility and their
propensity to chelate to and deactivate the palladium
catalyst.182040 | Chem. Sci., 2017, 8, 2039–2046Results and discussion
We previously reported the Suzuki–Myaura cross-coupling of
bromotryptophan-containing natural product analogues2e using
the Buchwald's water-soluble ligand sSPhos 11.19 Anderson and
Buchwald reported the use of water-soluble ligand sXPhos 12
for the Sonogashira coupling of aryl halides including chlor-
opyridine.19 We decided to explore whether this ligand could be
utilised to facilitate the Sonogashira coupling of halo-
tryptophans in water. To start with a slightly less challenging
substrate, we rst investigated whether Sonogashira modica-
tion of unprotected 5-bromoindole 15 could be achieved (Fig. 1).
Encouragingly, we were able to demonstrate the conversion
of 5-bromoindole 15 with phenylacetylene 16, in a 1 : 1 mixture
of water and acetonitrile to its alkynylated derivative 17 in 76%
conversion (Scheme 2, and Table 1, entry 1). This provided
a good starting point, however, we observed that increasing the
catalyst and ligand loading (from 2.5 to 5 mol% and from 7.5 to
15 mol%, respectively) improved the conversion to 93% (Table
1, entry 2). The reaction could be further improved by increasing
the number of equivalents of alkyne coupling partner from 1.5 eq.
to 3.0 eq., leading to complete conversion of 5-bromoindole 15 to
the cross-coupling product 17 (Table 1, entry 3). With conditions
in hand that enabled the cross-coupling of 5-bromoindole 15 to go
to completion, we sought to investigate if the reaction time could
be decreased. Switching from conventional heating to microwave
heating at 100 C proved to be successful, with full conversion
being observed aer 2 h heating in the microwave (Table 1,
entry 4), rather than the 18 h previously required.
Having established conditions to enable quantitative
conversion of 5-bromoindole 15 within 2 h, we next explored the
reaction with what we had perceived to be the more challenging
unprotected 5-bromotryptophan 18 (Scheme 3). Pleasingly, the
reaction proceeded remarkably well with the tryptophan
substrate and complete conversion to the product was observed
aer microwave heating for 2 h under the same conditions that
we had developed for 5-bromoindole 15 (Table 1, entry 5).
With the successful quantitative conversion of unprotected
5-bromotryptophan 18 accomplished, we next investigated theThis journal is © The Royal Society of Chemistry 2017
Table 1 Conditionsa for the Sonogashira cross-coupling reaction of 5-bromoindole 15 and 5-bromotryptophan 18 with phenylacetylene 16
Entry Substrate Cat/mol% Ligand/mol% Alkyne loading/eq. Heating method Reaction time/h NMR conv./%
1 15 2.5 7.5 1.5 Conventional 18 76b
2 15 5.0 15.0 1.5 Conventional 18 93b
3 15 5.0 15.0 3.0 Conventional 18 >99b
4 15 5.0 15.0 3.0 Microwave 2 >99b
5 18 5.0 15.0 3.0 Microwave 2 >99c
a Substrate (0.1 mmol), PdCl2(CH3CN)2 catalyst, sXPhos ligand 12, Cs2CO3 (2.5 eq.), phenylacetylene 16, CH3CN/H2O (1 : 1, 2 mL), sealed tube, 100C, solids and solvents purged with nitrogen. b Based on ratio of starting material aromatic peak at dH 6.50 ppm compared to product aromatic peak
at dH 6.56 ppm in CDCl3.
c Based on ratio of starting material aromatic peak at dH 7.89 ppm compared to product aromatic peak at dH 7.96 ppm in
CD3OD.
Scheme 3 Investigating the reaction of halo-tryptophans and phe-
nylacetylene 16. (a) Reagents and conditions are described in Tables 1
and 2.
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View Article Onlinelimits of the reaction and specically the impact of a series of
water-soluble ligands. In order to determine the broader
applicability we also explored the impact of air, the eﬀect of
substrate concentration on conversion, and the inuence of
temperature on the reaction (Table 2). To this end, we rst
investigated series of commercially available water-soluble
ligands, sSPhos 11 (88%), TPPTS 13 (50%) and TXPTS 14 (83%)
were all shown to mediate reasonable conversions of 5-bromo-
tryptophan 18 to the expected product 19 (Table 2, entries 2–4),
however, none of the ligands tested matched sXPhos 12 for
performance (Table 2, entry 1). The reactions to this point had
been carried out under inert conditions with de-gassed solvents,
not always simple to achieve for biomaterials. In order to
investigate the impact of air on the cross-coupling, the reaction
was repeated in air using non-degassed solvents (Table 2, entry
5). The reaction proceeded well in the presence of oxygen with
only a modest decrease in the observed conversion (86% with
respect to >99%, Table 2, entries 5 and 1, respectively). Our
results showed that an inert atmosphere was preferential for the
reaction. However, the reaction still proceeded to give high
conversion without the exclusion of oxygen from the reaction,
showing that the conditions should work well for reactions
where maintaining an inert atmosphere may prove diﬃcult.
We next focused on studying the eﬀect of concentration on
the reaction. The reaction was carried out at 50 mM, 25 mM andTable 2 Investigating the reaction of halo-tryptophans and phenylacety
impact of the ligand (entries 2–4), reaction in the presence of air (entry
chlorotryptophan 20 as substrate in place of 5-bromotryptophan 18 (en
Entry Substrate
Substrate amount in
mmol (concentration)
1 18 0.1 (50 mM)a
2 18 0.1 (50 mM)a
3 18 0.1 (50 mM)a
4 18 0.1 (50 mM)a
5 18 0.1 (50 mM)b
6 18 0.05 (25 mM)a
7 18 0.025 (12.5 mM)a
8 18 0.1 (50 mM)a
9 20 0.1 (50 mM)a
a Substrate (1 eq.), PdCl2(CH3CN)2 (5 mol%), ligand (15 mol%), Cs2CO3 (
heating, sealed tube, solids and solvents purged with nitrogen. b As witha
of starting material aromatic peak at dH 7.89 ppm compared to product a
This journal is © The Royal Society of Chemistry 201712.5 mM (Table 2, entries 1, 6 and 7, respectively). As expected,
the conversion is not as eﬃcient at lower concentrations,
however, modest conversion, using the same catalyst loading,
could be observed at a 4-fold dilution. There may be scope for
improving these conversions, by increasing catalyst loading and
coupling partner, when the halogenated substrate is at high
dilution. Finally, the eﬀects of lowering the temperature of the
reaction were investigated. We observed that a slight reduction
in reaction temperature from 100 C to 80 C (Table 2, entry 8)
signicantly decreased the observed conversion from >99% to
35%, indicating that 100 C was likely to be close to optimal for
this reaction.
Previous investigations of the Sonogashira cross-coupling have
focused predominantly on aryl iodides; and so it is exciting to see
that conditions can be developed to enable quantitativelene 16. Conversions achieved under various conditions: exploring the
5), concentration (entries 6 and 7), impact of temperature (entry 8), 5-
try 9)
Ligand T/C NMR conv.c/%
sXPhos 100 >99
sSPhos 100 88
TPPTS 100 50
TXPTS 100 83
sXPhos 100 86
sXPhos 100 67
sXPhos 100 34
sXPhos 80 35
sXPhos 100 <1
2.5 eq.), phenylacetylene (3.0 eq.), CH3CN/H2O (1 : 1, 2 mL), microwave
, except solids and solvents were not nitrogen purged. c Based on ratio
romatic peak at dH 7.96 ppm in CD3OD.
Chem. Sci., 2017, 8, 2039–2046 | 2041
Table 3 Reaction of halo-tryptophans with commercially available
phenylacetylenes 16, 24, 25 and ethynylthiophene 26a
Entry Tryptophan Alkyne Product Conversionb (yieldc)/%
1 5-Br 18 16 19 >99 (80)
2 6-Br 21 16 34 >99
3 7-Br 22 16 35 81
4 7-I 23 16 35 79
5 5-Br 18 24 36 >99 (97)
6 6-Br 21 24 37 >99
7 7-Br 22 24 38 >99
8 7-I 23 24 38 >99
9 5-Br 18 25 39 >99 (79)
10 6-Br 21 25 40 >99
11 7-Br 22 25 41 >99
12 7-I 23 25 41 >99
13 5-Br 18 26 42 >99 (75)
14 6-Br 21 26 43 >99
15 7-Br 22 26 44 >99
16 7-I 23 26 44 >99
a Substrate (0.1 mmol, 1.0 eq.), alkyne (0.3 mmol, 3.0 eq.),
PdCl2(CH3CN)2 (5 mol%), sXPhos (15 mol%), Cs2CO3 (2.5 eq.), water/
acetonitrile (1 : 1, 2 mL, degassed), microwave heating, 100 C, 2 h.
b Based on NMR ratios of starting material to product in CD3OD.
c Average of three isolated yields.
Scheme 4 Exploring the substrate scope of the reaction.
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View Article OnlineSonogashira conversion of the less reactive bromotryptophans.
The chloro analogues are even less reactive, but again in order to
determine the limitations of the reaction conditions, the reaction
of 5-chlorotryptophan 20 with phenylacetylene 16 was attempted
(Scheme 3 and Table 2, entry 9). Unfortunately, this highly
unreactive substrate showed no reaction aer heating for 2 h in
the microwave, with only starting material being observed.Table 4 Reaction of halo-tryptophans with commercially-available
alkynes 27–33a
Entry Tryptophan Alkyne Product Conversionb (yieldc)/%
1 5-Br 18 27 45 >99 (81)
2 6-Br 21 27 46 >99
3 7-Br 22 27 47 81
4 7-I 23 27 47 85
5 5-Br 18 28 48 63 (26)
6 6-Br 21 28 49 >99
7 7-Br 22 28 50 74
8 7-I 23 28 50 39
9 5-Br 18 29 51 54 (51)
10 6-Br 21 29 52 >99
11 7-Br 22 29 53 >99
12 7-I 23 29 53 56
13 5-Br 18 30 54 16
14 5-Br 18 30 54 50 (25d)
15 5-Br 18 31 55 <1
16 5-Br 18 32 56 <1
17 5-Br 18 33 57 <1
a Substrate (0.1 mmol, 1.0 eq.), alkyne (0.3 mmol, 3.0 eq.),
PdCl2(CH3CN)2 (5 mol%), sXPhos (15 mol%), Cs2CO3 (2.5 eq.), water/
acetonitrile (1 : 1, 2 mL, degassed), microwave heating, 100 C, 2 h.
b Based on NMR ratios of starting material to product in CD3OD.
c Average of three isolated yields. d Product co-eluted with sXPhos 4
and could not be isolated pure, the approximate yield is based on
a single isolation.
2042 | Chem. Sci., 2017, 8, 2039–2046With the optimal conditions for the Sonogashira coupling of
halotryptophans determined, we then sought to examine the
scope of the reaction by varying the halogen and its position, as
well as the alkyne coupling partner (Scheme 4, Tables 3 and 4). The
reactions were carried out with 5-bromotryptophan 18, 6-bromo-
tryptophan 21, 7-bromotryptophan 22 and 7-iodotryptophan 23
with a range of commercially available terminal alkynes (Scheme
4, 16, 24–33). In each reaction, the conversion of the starting halo-
tryptophan to the cross-coupled product was determined by 1H
NMR. To obtain indication as to representative isolable yields for
each alkynyl coupling partner, the product from reaction with the
5-bromotryptophan 18was puried to determine the isolated yield
(puried by reverse-phase HPLC and carried out in triplicate).
We rst examined the coupling of aromatic-substituted
acetylenes. The three phenylacetylene-based alkynes (phenyl-
acetylene 16, 3-uorophenylacetylene 24 and 4-cyanophenyla-
cetylene 25) all showed very good to excellent conversions for
each tryptophan and high yields for the isolated products
(Scheme 4 and Table 3). The high yield obtained for the 3-u-
orophenylacetylene 24 was particularly pleasing as this enables
an F label to be introduced into a molecule that can potentially
be used to follow the fate of a molecule. Though current reac-
tion times (2 h) are still rather long, there may be potential to
develop this chemistry further to enable labelling for PET.
Similarly, heterocyclic alkyne ethynylthiophene 26 showed
excellent conversions for all the tryptophans and high yield for
the isolated product (Table 3).
Next, a range of aliphatic alkynes, containing useful func-
tionality, and designed to introduce diﬀerent levels of challenge,
were investigated. Though the reaction, would not proceed with
propiolic acid 31 (Table 4, entry 15), propargylamine 32 (Table 4,
entry 16) or TMS acetylene (Table 4, entry 17), the cross-coupling
reaction with 4-butyn-1-ol 27 proceeded with high conversion
and high isolated yield for product 45 (Fig. 2) and provides an
alcohol substituent for potential further modication. The reac-
tion also proceeded with 4-phenyl-1-butyne 28 to give moderateThis journal is © The Royal Society of Chemistry 2017
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
N
ov
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
1/
7/
20
18
 1
:4
6:
15
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineto excellent conversions (Table 4, entries 5 to 8), but low isolated
yields of product 48. 1,7-Octadiyne 29 was chosen as a coupling
partner in order to gain access to a terminal alkyne in the coupled
product, in order to install an alkyne tag for subsequent alkyne–
azide cycloaddition reactions.20 Pleasingly, the reaction pro-
ceeded to give diyne product 51 in 51% yield (average of three
isolated yields), (Table 4, entry 9). 3-Cyclohexyl-1-propyne 30 was
also investigated as a potential coupling partner. Aer the stan-
dard reaction conditions (100 C in microwave, 2 h), 1H NMR
showed approximately 16% conversion to the product 54
(Table 4, entry 13). Increasing the reaction time to 8 h (Table 4,
entry 14) improved the conversion to 50%. The product was
puried by reverse-phase HPLC, but co-eluted with the sXPhos 12
ligand, and it was challenging to obtain a denitive isolated yield
in this case.
Remarkably, our simple scoping reactions revealed that the
developed Sonogashira cross-coupling reaction conditions
could be applied to the modication of halotryptophans and
could be carried out under aqueous conditions without the
need for copper salts and without the need to protect the amino
acid. We carried out analysis of the isolated products, as
a representative set, using Marfey's reagent (see ESI†).21 Our
analysis revealed no erosion of the enantiopurity of the trypto-
phans under the reaction conditions that we had employed (see
ESI†). With robust conditions for tryptophan diversication via
Sonogashira cross-coupling in hand, we next tested the reaction
with more complex halo-tryptophan-containing substrates.
We chose to design and synthesise two tripeptides containing
an N-terminal and an internal 7-bromotryptophan. Tripep-
tides 58 and 59 were synthesised (see ESI†) and were sub-
jected to the aqueous Sonogashira reaction conditions with
3-uorophenylacetylene 24 (Scheme 5), chosen for its highFig. 2 Isolated products from the coupling of 5-bromotryptophan 18,
along with isolated yields (from triplicate isolations).
This journal is © The Royal Society of Chemistry 2017eﬃciency as a coupling partner to free halotryptophans and
also due to the benet of being able to follow the reaction by
19F NMR. The reaction with Ala-(7-Br-Trp)-Phe 58 proceeded
to give product 60 in 47% isolated yield. The reaction of (7-Br-
Trp)-Ala-Phe 59 also gave expected product 61, pleasingly in
quantitative isolated yield. The lower isolated yield for
product 60 could potentially be due to the steric hindrance
and/or diﬃculties associated with purication due to poten-
tially reduced aqueous solubility. The quantitative conversion
of the 7-bromotryptophan residue at the N-terminus of this
tripeptide is striking and opens up the possibility of using this
methodology for the labelling, modication and modulation
of peptides.
Having demonstrated the ability to apply this methodology
to small peptides we next explored the reaction in the context of
natural products as a potential tool for use in GenoChemetic
analogue generation. The harnessing of biosynthetic pathways
to force the incorporation of a halogen into a natural product
provides a chemically orthogonal handle with the possibility for
selective modication. We have previously demonstrated that
the facile Suzuki–Miyaura cross coupling may be readily applied
to such systems.2f Cystargamide 62 (Scheme 6) is a 5-hydroxy-
tryptophan containing cyclic lipopeptide isolated from
Kitasatospora cystarginea.22 Though this compound has shown
no notable biological activity to date, a very close structural
analogue Q-6402 has been reported to inhibit phospholipase
A2.23 Cystargamide provides an interesting and challenging test
bed for GenoChemetic analogue generation: rstly because the
naturally incorporated tryptophan shows hydroxylation and
therefore the incorporation of other analogues of this amino
acid may prove challenging, secondly because the molecule
contains a number of functionalities that could potentially
impede the reaction, and thirdly because it is produced in fairly
low titre.22
We set out to explore whether halotryptophans could be
incorporated, through precursor directed biosynthesis, to
generate a halogenated analogue of this natural productScheme 5 Investigating the Sonogashira modiﬁcation of 7-bromo
tryptophan, as a component of a tripeptide with 3-ﬂuo-
rophenylacetylene 24. (a) Reagents and conditions: PdCl2(CH3CN)2 (5
mol%), sXPhos 12 (15 mol%), Cs2CO3 (2.5 eq.), H2O : CH3CN (1 : 1),
microwave heating, 100 C, 2 h.
Chem. Sci., 2017, 8, 2039–2046 | 2043
Scheme 6 Precursor-directed biosynthesis with K. cystarginea to
generate new-to-nature halo-analogues of cystargamide, a chal-
lenging test bed natural product system. Scale-up culture and Sono-
gashira reaction of semi-pure 6-bromo-cystargamide 9 with 3-
ﬂuorophenylacetylene 24 using the cross-coupling conditions that we
had developed. (a) Reagents and conditions: PdCl2(CH3CN)2 sXPhos
12, Cs2CO3, H2O : CH3CN (1 : 1), microwave heating, 100 C, 2 h.
Chemical Science Edge Article
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View Article Online(Scheme 6). To explore this possibility we carried out small scale
feeding experiments with 7-, 6- and 5-chlorotryptophan and 7-,
6- and 5-bromotryptophan at 0.25 mM and 1.0 mM to both 4 mL
cultures in 24 deep well plates and 50 mL cultures in 250 mL
Erlenmeyer asks. The cultures were extracted and analysed by
LC-MSMS. Results demonstrated that all of the halotryptophans
were incorporated into cystargamide, generating at low level,
a series of new to nature halogenated analogues (see ESI† for
details). As judged from the LC-absorbance peak area, there was
no signicant diﬀerence in the quantities of halo-cystargamide
produced across the two tryptophan concentrations that we had
carried out the precursor directed biosynthesis at, therefore, to
reduce wastage of halotryptophan precursor we opted for
a 0.25 mM concentration for future experiments. As we simply
wanted to explore and hopefully demonstrate proof of principle
by applying our Sonogashira methodology to the diversication
of a novel “new to nature” natural product we decided to select
just one halotryptophan for scaling up the fermentation with
and feeding.2044 | Chem. Sci., 2017, 8, 2039–2046Our challenge would be to generate suﬃcient halogenated
natural product on which to explore the cross-coupling. As we
had shown the chlorotryptophans to be too unreactive for
Sonogashira cross-coupling, and wanting to avoid placing
a halogen on C-5 of the indole ring, which is naturally hydroxy-
lated, and could provide a future chemically orthogonal handle
for further functionalization, we set out to scale up production
of 6-bromocystargamide. To this end we fed 8 L of culture
(incubated in batches of 500 mL in 2 L asks) with 0.26 mM
6-bromotryptophan. Extraction and purication resulted in an
approximately 1.0 mg of a partially pure fraction containing
brominated cystargamides along with other cystargamide
derivatives. By comparing the LC-MS extracted ion peak areas, it
could be estimated that the parent unhalogenated cystargamide
62, a bromo-cystargamide analogue that lacked the 5-hydroxy
on the tryptophan 63 and bromocystargamide 9, were present in
an approximate 10 : 0.2 : 1.4 ratio. This indicated the ability of
the producing organism to process 6-bromo-tryptophan,
though perhaps not quite as eﬃciently as unhalogenated tryp-
tophan. Analysis of the extract also revealed quantities of linear
unbrominated cystargamide in which the ester bond appeared
to have been hydrolysed, and analogues of this and the
brominated forms, which contained an alanine rather than
glycine residue (see ESI† for more details).
A fraction containing predominantly the brominated
analogue (>85%) 9 was subjected to the Sonogashira cross-
coupling conditions developed within this study (Scheme 6).
LC-MS analysis of the crude reaction mixture indicated that all
brominated cystargamide had been consumed and revealed
peaks at m/z 1072 [M + H]+ for product 64 and 1090 [M + H]+ for
hydrolysed product 65 (further conrmed by MSMS), indicating
successful cross-coupling with 3-uorophenylacetylene 24 into
analogue 9. As no corresponding linear brominated cys-
targamide had been present within the starting material, for
this reaction, it is likely that this second product arises from
hydrolysis of cystargamide either during the reaction or work
up. 19F{1H} NMR analysis showed two uorine peaks at dF(D2O)
114.05 and 114.43 ppm with a ddd coupling consistent with
that observed for compounds 36, 60 and 61. Attempts to sepa-
rate the very small amounts of the two compounds by HPLC
proved to be unsuccessful, as was obtaining suﬃcient material
for 1H NMR analysis. It was notable though that the conditions
that we had developed could be used to enable the functional-
ization of a challenging “new to nature” natural product even
within a chemically demanding test-bed system with the added
challenge of being produced only at very low level.Conclusions
We have for the rst time demonstrated the Sonogashira
diversication of free unprotected 5-, 6- and 7-bromo trypto-
phan and 7-iodotryptophan, and shown the reaction to be very
high yielding with phenylacetylene 16, uorophenylacetylene
24, 4-cyanophenylacetylene 25 and ethynylthiophene 26. The
reaction products can be isolated by reverse-phase HPLC and
show no loss of stereochemical integrity under the reactionThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineconditions. The reaction can even be carried out in the presence
of oxygen with only a small decrease in the observed conversion.
Tryptophan is an essential amino acid, it is a key component
in many natural products and its presence in proteins and
peptides is key to their structural integrity, furthermore the
intrinsic uorescence of tryptophan oen determines, or
modulates, the spectrophotometric properties of a given
peptide or protein, it therefore represents a very exciting target
for diversication. Sonogashira cross-coupling of other amino
acid residues including iodophenylalanine has been shown to
be useful to tagging or modulating the properties of these
peptides. We have demonstrated the rst Sonogashira modi-
cation of halotryptophan as a component of a peptide, this
represents a starting point from which milder conditions must
be developed in order to extend the applicability of this reaction
to sensitive proteins.
Using a simple tripeptide containing a 7-bromotryptophan
at the N-terminus we have been able achieve quantitative
Sonogashira cross-coupling with 3-uorophenylacetylene 24
within 2 h. This is exciting as it opens up the potential for
development for 19F labelling of peptides, with the short reac-
tion times making this a potentially attractive tool for PET
imaging studies.
We have for the rst time generated a series of “new to
nature” halocystargamides including 6-bromocystargamide 9.
The enzymes that mediate the biosynthesis of these compounds
are strikingly exible in enabling the incorporation of a wide
range of halogens at diﬀerent positions around the indole ring.
Full processing including hydroxylation of the bromo-
tryptophan observed within the natural product, demonstrates
how readily, even the sterically bulky C–Br, is tolerated by the
biosynthetic enzymes. 6-Bromocystargamide 9 represented the
demanding natural product test-bed desired with which to
challenge the cross-coupling conditions that we had developed.
Though the compound is functionally elaborate and can only be
accessed in very small quantities, it was possible to selectively
functionalise the molecule with 3-uorophenylacetylene 24
using the conditions that we had developed. Previously we had
exemplied the utility of the more forgiving Suzuki–Miyaura
reaction in the selective modication of natural products; here
we show that the Sonogashira reaction can be used as a tool for
GenoChemetics and for the selective diversication of “new to
nature” natural products. Such an approach hold the potential
to be a useful tool for diversication for Structure Activity
Relationship (SAR) studies, for modulating the electronics of
tryptophan and for tagging natural products and proteins with
labels for uorescence tracking, immobilisation tagging and
PET imaging.
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